Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)

NCT06476210 is registered in ClinicalTrials.gov with Beijing Chest Hospital as lead sponsor.

NCT NCT06476210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06476210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)
Lead sponsor
Beijing Chest Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
June 30, 2024
Completion date
June 30, 2026
Enrollment
45 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary tuberculosis